Viracta Therapeutics to Present at Upcoming Investor Conferences
Viracta Therapeutics, Inc. (Nasdaq: VIRX) has announced its leadership will present at four investor conferences in November 2022. Presentations include:
- Stifel 2022 Healthcare Conference on November 15, 2022, at 3:35 PM ET
- 13th Annual Jefferies London Healthcare Conference on November 16, 2022, at 5:35 PM GMT / 12:35 PM ET
- Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 10:30 AM ET
- 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 1:50 PM ET
Webcasts will be available on their website.
- None.
- None.
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated cancers, today announced that company leadership is scheduled to present and participate in one-on-one meetings at four investor conferences in November.
| Stifel 2022 Healthcare Conference (in-person) | |
| Presentation Date: | Tuesday, November 15, 2022 |
| Presentation Time: | 3:35 PM ET |
| Format: | Formal presentation |
| Presenter: | Dan Chevallard, Chief Operating Officer and Chief Financial Officer |
| 13th Annual Jefferies London Healthcare Conference (in-person) | |
| Presentation Date: | Wednesday, November 16, 2022 |
| Presentation Time: | 5:35 PM GMT / 12:35 PM ET |
| Format: | Formal presentation |
| Presenter: | Mark Rothera, President and Chief Executive Officer |
| Piper Sandler 34th Annual Healthcare Conference (in-person) | |
| Presentation Date: | Tuesday, November 29, 2022 |
| Presentation Time: | 10:30 AM ET |
| Format: | Formal presentation |
| Presenter: | Mark Rothera |
| 5th Annual Evercore ISI HealthCONx Conference (virtual) | |
| Presentation Date: | Wednesday, November 30, 2022 |
| Presentation Time: | 1:50 PM ET |
| Format: | Fireside chat |
| Presenters: | Mark Rothera and Lisa Rojkjaer, Chief Medical Officer |
A live webcast of each presentation will be available on the Investors section of the Viracta website under “Events and Webcasts” at https://viracta.investorroom.com/events-and-webcasts. The webcasts will be archived for at least 30 days following the presentation.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company focused on the treatment of virus-associated cancers. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent/metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
FAQ
When is Viracta Therapeutics presenting at the Stifel 2022 Healthcare Conference?
Who will represent Viracta Therapeutics at the Jefferies London Healthcare Conference?
What is the date and time of Viracta's presentation at the Piper Sandler Conference?
Is there a webcast available for Viracta's presentations?
What is the main focus of Viracta Therapeutics?
